The Operational QoE™ Thesis

Recently I posted the “2026 Dental M&A Thesis”, where I discussed why 75% of DSOs that went to market failed to close, and how the era of buying cheap and selling high on multiple expansion is over. It resonated with a lot of M&A teams, brokers, and dental operators, because everyone is already feeling the problem. Simply put, returns now have to come from how the practice is actually run.

As a result, the obvious question today which nobody has a clean answer to, is this:

If returns now come from how a practice is run, how do you actually measure that, in dollars, before you buy it or sell it?

That question is what DRAI exists to answer. It's not about what the seller says, or what the financials imply, but what is actually true.

We measure it, and we coined it the Operational Quality of Earnings.

The Operational QoE answers two questions a Financial QoE was never built to touch: how much more could this practice earn from the patients it already has, and will the earnings you are paying for still be there in two, three, five years?

Knowing the answers is not a “nice to have”. It decides real value on both sides of the table.

General awareness is not alpha. Specificity is.

For a buyer, not knowing the specifics costs you in two areas.

The first is price. You pay a multiple of EBITDA, so the number that actually matters most is not what the practice booked in the last few years but the EBITDA that it can sustainably produce going forward. Almost every practice has recoverable production sitting in its own patient base that never reaches the financials, which means the realistic, achievable earnings are higher than the trailing numbers suggest.

What buyers do today is price off the trailing financials, confirm them with a financial QoE, and make a vague assumption that there is probably some upside to capture once they own it. But that assumption is just that, an assumption. There is no real number attached to it, so it cannot go into the model, the bid, or the plan in any concrete way. It sits in the back of your mind as “this should get better,” and the actual work of finding out how much better only starts after you have already bought it.

That's why we put a real number on it before you price. How much upside is realistically in this practice, where it sits, what is causing it, and what it would take to capture, modeled conservatively and broken out by category and location, in a form your investment committee will accept. That is the whole difference. You price and forecast the way you always have, except the upside in your model is now a measured figure you can stand behind instead of a hope, so you underwrite the real return with conviction, pay the right price rather than guess at it, and structure the deal around what is actually there. In a market where the easy multiple-expansion returns are gone, that is the edge, and the fee is a rounding error against the size of the deal.

The second cost is time. Here's the thing, buyers know that upside potential exists. Of course they know opportunity is there. But knowing “there's likely room to improve recall and unscheduled treatment conversions” is not something you can price, underwrite, or hand to your team as a plan, while a number, broken out by category, location, and root cause, is. Without that, the work of turning assumptions into a real plan only starts after the wire clears, when your integration team pulls the reports, finds the gaps, builds the plan, and finally starts executing. That's usually many months in because they are doing it reactively while also absorbing staffing, systems, and everything else a new practice brings.

In a leveraged hold, every month of that delay is expensive. Earnings recovered in month three compound across almost the entire hold and sit in the trailing numbers you eventually sell on, while the same earnings recovered in month fifteen compound across far less and may never reach the exit multiple at all. The distance between executing on day one and discovering over year one is a real difference in IRR, on upside that was always there.

For a seller, the same gap in specifics costs you twice too.

Any recoverable production you never captured is revenue the practice could have earned and simply did not, so it never showed up in your numbers. And because a practice sells for a multiple of its EBITDA, every dollar of EBITDA missing from those numbers is several dollars off your final price. Capture even $200,000 of recoverable production into your trailing EBITDA before you list, and at a normal multiple that is well over $1 million of additional sale price. Since a practice's overhead is largely fixed, almost all of that recovered revenue falls to the bottom line. But if you leave the recoverable revenue unknown, it'll remain as untapped potential, a missed opportunity.

Second, the gaps you do not document become the buyer's leverage, which is why you want to control the narrative going in. In diligence, an operational weakness the buyer finds that you cannot strongly explain gets treated as risk which is discounted far beyond the risk it actually represents, because an unexplained problem always looks bigger than a measured one. So if you proactively walk in with that same gap already quantified and framed as a fixable operational issue with a known dollar value, it gets priced for what it is instead of used to re-trade you down while you scramble to respond.

That is the problem on both sides. The Operational QoE is the document that closes it.

What the Operational QoE actually is

It finds the value a practice is leaving on the table and the risks hiding inside its earnings, measured both in dollars from the practice's own data, and hands over the exact roadmap of what to do about it.

It's independent, evidence-based, and built to stand up in a data room alongside the financial QoE. We only do the measuring, not the fixing, and that's deliberate. A number only carries weight in a deal room if the firm producing it has nothing to gain from the answer. Staying independent is what makes the number trusted by both sides. The revenue recovery work itself goes to the client's own team.

The five categories we look at, and why these five

• Lapsed recall. Patients who completed treatment, were due back, and fell off the schedule. Usually the single largest pool because recall is the recurring revenue engine of a practice and it leaks slowly enough that nobody notices the size of it.
• Unscheduled treatment. Cases the dentist diagnosed and the patient accepted, that never got booked into a chair. The highest-probability untapped value in the building because the patient already said yes.
• No-shows and cancellations. Chair time that was sold and then lost, with no system to recover it.
• Provider variance. Two clinicians working the same patient flow and the same schedule, producing very different numbers. It shows where capacity is being left on the table and whether production is replicable or quietly dependent on one person.
• New patient retention. Patients a practice paid $300 to $500 to acquire, seen once and never brought back. The difference between growth that compounds and a treadmill that just looks like growth.

These five matter for a reason: each is large enough on its own to move a deal, each sits in the practice's own data so it can be proven rather than asserted, and each traces to a specific root cause a new owner can actually fix. Since the capacity to deliver this production already exists, almost all of it converts straight to EBITDA once captured, which is what makes it move valuation at the multiple. None of it is owed to the practice, it's production the practice is capable of and simply is not capturing, invisible on a financial statement because none of it ever generated a billing event.

If it's so obvious, why is the value still untapped?

None of these five categories are a secret, and any operator reading this already knows practices leak revenue in those areas. That's exactly the point: the problem was never that the categories are hidden, it's that in the context of M&A, for practices actually on the table when someone is about to buy it or sell it, nobody has measured the actual untapped revenue, where it sits and what is causing each gap to a standard anyone can act on.

There are a handful of structural reasons for why this has been the case, deal after deal.

• Bandwidth. In a live transaction the deal team is consumed by the deal, and after close the integration team is absorbing staffing, systems, and several practices at once. Nobody has the room to go through one practice's operations in the kind of detail this takes, and pin down exactly where the money is leaking, while the clock is running.
• Complacency. When a practice or a group is growing or simply doing fine, the leakage never feels urgent enough to dig into. Good enough wins, and the true size of what is being left behind stays invisible.
• It's nobody's actual job, because it falls in the gap between two skill sets. The analysts running a deal know finance, not the true day-to-day reality of how a dental practice actually runs. The operators who know that reality cannot usually translate it into what it is worth in a transaction. The whole job is the bridge between the two, reading the operation and converting it into dollars on the valuation, and that is a different discipline from doing deals, practising dentistry, or moving listings. It is the only one we do.

Also, you cannot credibly mark your own homework. A number the seller produces or the buyer's own team produces carries little weight in a deal room, because everyone there knows who it benefits. The figure has to come from someone with nothing to gain from the answer.

Not to mention, the tools they already have were built for something else entirely. A practice management system like Dentrix or Open Dental stores the data and prints reports, it does not interpret them for a transaction. And analytics or intelligence platforms like Dental Intelligence or Jarvis are an ongoing operating tool a practice runs on itself, day to day, to watch its own numbers. Both are genuinely useful, but neither is built for a deal room nor hands a buyer or a seller an independent, normalized, benchmarked, root-caused dollar figure of recoverable production and earnings risk with a firm's name standing behind it.

A dashboard helps you run a practice you already own, but an Operational QoE tells you a practice's true potential and what is really inside it at the moment it changes hands. That is the gap, and it is the whole reason we exist. We are not another vendor handing you a dashboard. We are the independent partner that does the simple, unglamorous, neglected work, at depth, on the clock, as an extension of your side of the deal, at every stage of the journey.

What the gaps usually look like

They are rarely small, and they are rarely where an owner expects. A group can be running full schedules and growing collections while several thousand patients sit outside recall, because the person who ran the recall process left and the process left with them. Accepted treatment accumulates in the ledger for years, in six figures on a mid-sized group, because the practice did the hard part, the diagnosis and the patient's yes, and never put the work in a chair. No-shows run at double the rate in some locations of the same group compared to others, for reasons nobody has looked into. And new patients that cost several hundred dollars each to acquire get seen once and never brought back, while the practice keeps spending to replace them.

The point is not the range. It is that none of it appears anywhere in the financials, because none of it ever generated a charge, so the only way to know the size of it in a particular practice is to measure that practice. That is what the engagement produces: the figure for the group in front of you, not an industry average.

Operational QoE: for buyers

For a buyer acquiring and expanding a group, an Acquisition Diligence Operational QoE does two jobs.

The first is quantifying the upside. We measure the recoverable production sitting in the practice, where it sits and what it's worth so that you go into the deal knowing what the practice can sustainably produce long-term, and why.

It is a specific, located, root-caused figure for this practice, with conservative conversion assumptions you can defend to a committee. It is quantified, recoverable upside to that same EBITDA, which nobody else has measured, so it tells you the real return the deal can produce before you commit. Broken out by category and location, that lets you underwrite with conviction, pay the right price rather than guess at it, and judge whether the deal clears your return bar at all. A corporate development lead at one of the largest DSOs recently told me that knowing the recoverable revenue before close would change what they are willing to pay for a practice. And the day you close, your team runs a recovery plan that is already built and prioritized instead of spending months working out where the upside is in this specific practice. Since you start capturing quicker than you normally would have, that same recovery lifts the IRR across the hold.

The second job is the durability of those earnings. A financial QoE confirms what the practice earned, but not whether the operations producing those earnings are healthy. Standard diligence handles the obvious risks, like a selling dentist's transition, through deal structure. What it does not quantify is the trajectory underneath the revenue line: whether the active patient base is growing or shrinking while fee increases prop up the top line, and whether new-patient growth is being retained or churning straight back out. A practice can look stable on the P&L while the base that feeds it hollows out, and for a buyer paying a multiple of today's EBITDA, that is the difference between earnings that compound and earnings that fade. It lives in the patient data, not the financials. A healthcare banker who has financed hundreds of these deals put it in perspective for me: he underwrites seven-figure loans on practices' financials and has never once seen an operational read like this in a deal. The people with the most capital at risk are working off half the picture, which is exactly the edge for the ones who stop doing that.

The value compounds at scale. On a single acquisition the edge can look modest, a slightly sharper price, some upside reached a few months sooner. But a platform is not buying one practice, it's buying twenty, forty, eighty a year, and that edge multiplies across every one of them. A serious acquirer was always going to create value in the practices it buys, so the difference is not whether value gets created, it is how much of it actually gets captured and how fast you get there. Walking in with a measured number means you capture more of what is genuinely in the practice instead of leaving part of it sitting there, you start on day one rather than months later once your team has finally worked the practice out for itself, and you do it with far less friction than reconstructing it reactively after close. Even an extra $100,000 per deal that you would otherwise have left uncaptured or only reached too late, across 40 acquisitions, is $4 million of EBITDA you would not have had, and at an 8x exit roughly $32 million of enterprise value, on top of the returns you were always going to make anyway. And because earnings recovered early compound across almost the whole hold, getting to them on day one instead of a year in lifts the IRR on every deal you do. That same read protects you on the deals where the earnings were quietly fading or the growth was a treadmill, the ones you reprice or walk away from before they ever reach your portfolio. One sharp read is a good deal. The same read on every deal, every year, is the difference between a platform that compounds and one that quietly wonders why its returns keep lagging its model.

Operational QoE: for sellers

You have two moments to use this, and they do different jobs.

With real runway before a sale, a Pre-Listing Operational QoE measures the recoverable revenue and gives you the roadmap to capture it into EBITDA before you go to market. The logic is simple: lift your actual EBITDA before you list, and because the price is a multiple of that EBITDA, you sell for more, on numbers you genuinely improved, while pocketing the extra profit in the months before the sale. A dental exit-planning specialist ran the math on a call: find an owner $300,000 of recoverable EBITDA, and at a 7x multiple once captured you have added $2.1 million to the sale price.

When the listing is close, a Going to Market Operational QoE hands you control of the narrative so the buyer's diligence cannot drive it. Normally the buyer finds the gaps and uses each one to re-trade you down. Walk in with the operational picture already documented and there is nothing left to discover and weaponize, because a known gap gets priced fairly while an unknown one gets discounted far past its real size. It also strengthens the earn-out terms which usually hang on future performance neither side fully controls, which is why so many never pay out. So if you build it on dormant assets that already exist, the accepted treatment and lapsed patients sitting on the books, you get paid for value you already created once it's converted. As a broker with twenty-five years on the sell side put it, owners and their advisors usually do not know how to find or structure this themselves. That is the gap we fill, working alongside the brokers, advisors, and attorneys around the deal.

The Operational QoE as the standard for dental M&A

It can be used once, for a single transaction, or across the whole lifecycle of the business. For most operators, it should not be a one-time thing.

A buyer acquiring once, or an owner selling once, get the full value from a single engagement. But the same recoverable revenue and the same risk to whether the earnings will hold sit underneath every major decision a group makes, which is why the operators who treat this as a standing part of how they run tend to compound the advantage.

On the practices a group already owns and intends to keep, with no deal anywhere in sight, a Portfolio Operational QoE Review finds the leakage dragging current earnings and hands over the roadmap to recover it, purely to make the business they already own worth more and run better. This is for operating use, an internal tool, not a deal document. And when the group acquires, an Acquisition Diligence Operational QoE on each target means it makes their decisions on real, achievable earnings and sidesteps the deals that look better than they are. When the group prepares to sell, a Pre-Listing Operational QoE captures the upside into the trailing earnings buyers will price on. And as it lists, a Going to Market Operational QoE documents the operational picture so it controls the story and the buyer's diligence cannot chip the valuation.

The reason this matters even for groups that are already winning is simple: nobody measures this layer as a standardized number, so even strong operators are leaving real money in it without knowing the size of it. Good practices still have lapsed patients and unbooked treatment. Growing groups still buy practices here and there whose growth was never sustainable. The difference between a group that does great and one that consistently, decisively outperforms is rarely the big strategic moves; it is whether they capture the value everyone else leaves on the table, deal after deal, year after year. That is why we recommend it as the standard.

Example of a 12-location DSO using the Operational QoE

Picture a 12-location group with around $24 million in collections that is planning to grow for a few years and then sell. The numbers below are illustrative and deliberately conservative, but the shape is how this plays out.

It starts with a Portfolio Operational QoE Review on the 12 locations it already owns, when there's no deals in sight. The review surfaces roughly $700,000 a year of recoverable production sitting across the group: lapsed patients no one is reactivating, treatment already accepted and never booked, two locations whose providers are producing well below the rest. The group works the roadmap over the next year and captures most of it, lifting earnings by around $500,000. At the roughly 8 times earnings a platform this size trades on, that is $4 million of enterprise value created before it buys a single thing.

Over that same year it acquires five practices, one at a time, and runs an Acquisition Diligence Operational QoE on each. Across the five, the analysis finds about $400,000 of recoverable revenue the group can start capturing the day each deal closes. It also catches two things the financials hid. On one target, revenue looks steady but the active patient base has been shrinking for two years behind a string of fee increases, so the earnings are set to fade rather than hold, and the group reprices and restructures around that instead of paying for growth that is not coming. On another, the new patients driving the growth story are barely being retained, so that growth is a treadmill, and the group negotiates roughly $300,000 off the price. Five deals, each priced on what is actually there instead of what the seller's numbers implied.

A couple of years later, now 17 locations and ready to exit, the group runs a Pre-Listing Operational QoE. It surfaces another $600,000 of recoverable production built up across the larger group, and the group captures it into earnings before going to market, lifting the trailing number by about $500,000. At 8 times, that is another $4 million on the sale price, built entirely from patients it already had. Then, as it lists, a Going to Market Operational QoE documents the operational picture so the buyer's diligence has nothing to discover and weaponize, and the earn-out is built on assets already on the books rather than promises about the future.

What happens without the Operational QoE

Now imagine if the same 12-location DSO had never used the Operational QoE.

The $700,000 of portfolio leakage stays invisible, dragging earnings every single year and costing roughly $4 million of enterprise value it never builds. It overpays on the practice whose base was fading, watches those earnings underperform the model, and absorbs the loss after the wire clears. It pays full freight for the treadmill practice, the $300,000 it could have negotiated off gone. It lists on lower earnings and leaves the pre-listing upside, another $4 million of sale price, on the table. And at the closing table, the buyer finds the undocumented gaps and grinds the price down anyway, comfortably another $500,000. Same group, practices, and market. The only variable is whether anyone measured the recoverable revenue and the earnings risk before each decision. Across the cycle, that variable is worth the better part of $10 million, before you even count what the captured earnings would have compounded into over the hold. That is the difference between a group that meaningfully outperforms and one that never quite understands why its returns lagged the high expectations.

How an engagement runs

The engagement is built to run alongside a deal that is already moving, as an extension of your side of it rather than another firm parachuting in. The process is the same whether you are buying or selling.

• A scoping call. Fit, location count, deal stage, timing, and how you intend to use the report. One day.
• Paperwork. A mutual NDA and an engagement letter. One to three days.
• Intake and the data request, sent together. We work through one coordinator on your side, usually the VP of operations, the COO, or a regional manager. The coordinator completes a short group overview form, and each office manager completes a short per-location form and exports a fixed set of standard reports from the practice management system, each covering the trailing 24 months, uploaded through a secure Dropbox file request we provide: recall and continuing care statistics; treatment plan approval, presented, accepted and completed, by provider; the schedule summary, scheduled, completed, canceled and failed, by month; provider production and collections; patient activity, the active count and patients with no visit in 12 months or more; new patients by month; and the adjustment summary, so the conversion to cash runs on the practice's own write-off rate. Counts and totals only, no names, no ID numbers, no dates of birth, so a mutual NDA covers it and no business associate agreement is needed. When we work with a buyer on acquisition diligence, the seller's side facilitates the export and the files come to us from that side, which keeps the analysis independent of the buyer. Three to five days.
• Analysis. We standardize the exports, measure the opportunity in each of the five categories, trace each one to its probable driver, and convert it into dollars on your own cost stack. If anything material cannot be settled from the data alone, one batched set of written questions goes to the coordinator. Two to three weeks.
• Delivery. Within four weeks of complete data, into your data room or by secure link, to the party who commissioned it and nobody else. A buyer's findings stay with the buyer, a seller's never reach the buyer. Questions are answered in writing, and a walkthrough of the findings is available on request.
• Follow-up. At 6, 12, and 24 months we compare the report's figures against what was recovered, at no cost, so you see whether the number held.

Start to finish it runs in weeks, alongside the work already happening, and we never need your model or your own analysis.

Why DRAI

We do one thing, in one industry: we turn dental practice data into what a practice is actually worth in a deal. Not healthcare broadly, not operations in general. Dental practices, every single day. That focus is the whole product. It is what lets us benchmark a target against the dental practices we have already measured, trace each gap to a root cause we have seen before, and put a defensible number on it, the kind of depth you only get from looking at the same thing, deal after deal, and nothing else.

Every engagement makes the next one sharper. We are building a record of what we measured before a deal and what actually happened after it, practice by practice, deal by deal. Over time that becomes a proprietary picture of cause and effect in dental operations: what a given gap is really worth, which problems are fixable and which are not, and how an estimate made before close compares to the recovery after it. Nobody can buy that dataset. It only comes from doing the work at volume, and it makes every number we put out more defensible than the last.

We put our name on the numbers and stand behind it. In a world where anyone can generate a confident-looking analysis with AI in an afternoon, a firm that stakes its reputation on the number being right is a fundamentally different thing from a document that just looks the part.

Also, we were first. Nobody else was putting an independent dollar figure on the operational side of a dental deal, the recoverable revenue and the durability of the earnings, to a standard a data room would accept. We defined that and named it the Operational QoE. When it becomes a normal part of how dental deals get done, and it will, it gets done in the shape we built, the way quality of earnings itself went from a novel idea to something no serious deal closes without.

Who this is for

This is built for the owner or group that is business-minded and treats a practice as an asset, not just a job and passion-project, and would rather find the gaps and fix them rather than hand a buyer all the room for growth.

On the other hand, it's built for the serious acquirer, a DSO, a private equity platform, a strategic buyer, who wants to know exactly what they are buying, exactly what they can pull out of it, and exactly where the risk sits, before they commit.

It works on a single practice, emerging and mid-sized groups, and on platform-scale transactions. And it works for the people around the deal, the brokers, advisors, and attorneys who want their client's transaction to close clean and at the right number.

Is it a zero-sum game? Not entirely, but as you can tell there's definitely asymmetric leverage to whoever holds the alpha in a given transaction.

We take a limited number of engagements at once, because each one sits inside a live deal with a real clock and we protect our turnaround. If your deal is time-sensitive and we are already at capacity, we will tell you straight and give you a date for when we could be available.

About DRAI, and why now

I'm Andres, the founder of DRAI.

I was born in Venezuela and moved to Australia when I was five with my parents. Now I live between the US and Australia.

For most of my childhood I wanted to be a doctor, I grew up genuinely obsessed with medicine and healthcare was never abstract to me. I actually spent more of my own time in hospitals and having operations than most kids do, and dentistry in particular left a mark on me because an orthodontist who fixed my breathing and my bite as a teenager is a big part of why I care about this field at all.

I did not end up in medicine, entrepreneurship pulled me in harder, but the pull toward healthcare never left, and it's no accident that the thing I've bet my twenties on sits right where this industry and real value meet.

Before DRAI, my work sat in valuation and early-stage investing. I did marketing and business development for venture-backed companies, and I spent years taking my own positions on what young companies were worth and then living with those calls. Pricing an asset on what is in front of you, rather than what it claims to be, and being accountable for that judgment, is the exact discipline this firm runs on. It also taught me, mostly the expensive way, the lesson that became DRAI's whole premise: making money and keeping it are two different skills. The durable returns never came from chasing the next exciting thing. They came from the unglamorous fundamentals, retention over acquisition, systems built to monitor what matters, staying proactive instead of reactive, and an honest read on the numbers, the bridge between how a business truly runs and what it is worth. Every business I touched told the same story: everyone obsesses over winning the next customer while quietly bleeding the customers, and the revenue, they already have. That is the thesis behind DRAI.

The way I am wired is to look at how an industry actually works, find the place where everyone has quietly agreed not to look, and go straight at it. In dental M&A that place was obvious once I saw it: hundreds of millions of dollars change hands every year on financials checked to the decimal, while the operational reality underneath, the thing that actually determines whether those earnings hold, almost never gets verified independently, and never to the depth a financial QoE brings to the books. I didn't invent that gap, I just refused to accept this is how it has always been done as a good enough reason for it to stay that way. Then I spent months pressure-testing the idea against the most experienced people in the industry: brokers, M&A attorneys, healthcare bankers, DSO founders, partners at financial QoE firms, venture partners, board directors and more. Every one of them told me the same thing from inside their own corner of it: this is real, it is big, and nobody is doing it.

So here is the future I foresee, and the bet I am making: one day, no dental practice will change hands without an independent read on what it can really earn and whether those earnings will last, measured in dollars, the same way no serious deal closes without a financial QoE today, and DRAI is going to be the firm that made that the standard. It will not happen overnight, because changing how an industry runs its diligence is slow, and proof has to arrive before belief does. But the shift that makes it inevitable is already here, and the edge is always biggest before everyone has it. The brokers, advisors, and buyers who build this into how they work now are the ones who win the next decade of dental M&A.

To summarize

• A financial QoE confirms the earnings were real. The Operational QoE answers the two questions it cannot: how much more the practice can earn from the patients it already has, and whether those earnings will hold.
• We measure five categories of recoverable production, lapsed recall, unscheduled treatment, no-shows and cancellations, provider variance, and new patient retention, in dollars, from the practice's own data, and hand over the roadmap to capture it.
• None of it is secret. It goes uncaptured because nobody measures it independently, at depth, before the deal, and the tools practices already run were built to operate a practice, not to value one. This is the gap DRAI solves.
• For buyers: price each deal on real, measured potential instead of a guess, build your value-creation plan around exactly where the upside sits, and capture it from day one so it compounds across the hold and lifts your IRR.
• For sellers: capture the upside into your trailing earnings before you list, and walk into diligence with the gaps already documented so they get priced fairly instead of used against you.
• Independent by design. We run the analysis but we do not run the recovery. We have no incentive to inflate the numbers, so both sides of the table can trust it.
• One standard across the whole lifecycle: a Portfolio Review on what you own, Acquisition Diligence on what you buy, and Pre-Listing then Going to Market on what you sell.
• A new category, defined and named by DRAI. The edge is always biggest before everyone has it.